<DOC>
	<DOCNO>NCT02307149</DOCNO>
	<brief_summary>The study use establish dose CAVATAK ipilimumab patient advance melanoma ipilimumab would consider standard care . Treatment CAVATAK day 1 , 3 , 5 8 agent co-administered day 22 , 43 , 64 85 . Patients clinical benefit continue CAVATAK every 3 week one year ,</brief_summary>
	<brief_title>Study Intratumoral CAVATAK™ ( Coxsackievirus A21 ) Ipilimumab Patients With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Coxsackievirus Infections</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients metastatic unresectable stage IIIc IV melanoma treatment ipilimumab indicate At least one tumor must qualify target lesion irRCWHO ECOG 01 Women childbearing potential must negative serum urine pregnancy test perform within 72 hour prior start treatment No active bleed Life expectancy &gt; 12 week Prior ipilimumab treatment metastatic melanoma ( prior ipilimumab adjuvant permit ≥ grade 3 toxicity ) Tumors inject lie mucosal region close airway , major blood vessel spinal cord could cause occlusion compression due tumor swell erosion Active autoimmune disease ( exclude autoimmune thyroiditis vitiligo ) Patients history colitis Untreated brain metastasis . Other active metastatic cancer require treatment Active infection require antibiotic Pregnant lactate woman Need chronic steroid Within 28 day enrollment : WBC &lt; 3.1 x 10⁹ /L ; Hgb &lt; 9.0 g/dL ; AST ALT &gt; 1.5 upper limit normal ( ULN ) ; total bilirubin &gt; 1.9 g/dL ; prior HIV ; prior Hepatitis B ; prior Hepatitis C ; INR &gt; 1.5 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>